Pila Pharma Q2’22: An Aspiring TRPV1 Platform Company

Research Note



Redeye comments on Pila Pharma’s Q2 report. Highlights from the quarter include receiving ODD for XEN-D0501 and the commencement of the toxicological studies with XEN-DIA. We fine-tune our valuation model.


Filip Einarsson

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.